InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.77%
)
US TECH 100
19,408.75
(
1.26%
)
Dow Jones
38,778.10
(
0.49%
)
Brent Oil
83.65
(
-0.30%
)
Bitcoin
65,278.04
(
-1.82%
)
Post# of 252233
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: genisi post# 162825

Friday, 06/21/2013 9:45:06 PM

Friday, June 21, 2013 9:45:06 PM

Post# of 252233

Note that PLX is going for inhaled formulation and they will know the results from KMDA's phase II/III of inhaled AAT in the same indication by early 2014. Interesting also since Kamada has an orphan drug designation in both EU and US.

Are you suggesting PLX may not have a path forward in AAT if KMDA is successful? I saw a prior post from last year where you indicated you didn't think PLX could work around AMGN's patents on its anti-TNF drug.

In general, are you a fan of PLX risk-reward here?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up